Idursulfase

Idursulfase

Idursulfase

Add article description

Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II).[2] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

Quick Facts Clinical data, AHFS/Drugs.com ...

It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[3][4][5]

References

  1. [1]
    "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. [2]
    Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
  3. [3]
    "Drug approved to treat rare but potentially deadly disease". Archived from the original on 2011-02-24. Retrieved 2011-04-29.
  4. [4]
    Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
  5. [5]
    , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Idursulfase, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.